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Summary
Background The length of time that people with HIV on antiretroviral therapy (ART) with viral load suppression will 
be able to continue before developing viral rebound is unknown. We aimed to investigate the rate of first viral rebound 
in people that have achieved initial suppression with ART, to determine factors associated with viral rebound, and to 
use these estimates to predict long-term durability of viral suppression.
Methods The UK Collaborative HIV Cohort (UK CHIC) Study is an ongoing multicentre cohort study that brings 
together in a standardised format data on people with HIV attending clinics around the UK. We included participants 
who started ART with three or more drugs and who had achieved viral suppression (≤50 copies per mL) by 9 months 
after the start of ART (baseline). Viral rebound was defined as the first single viral load of more than 200 copies per mL 
or treatment interruption (for ≥1 month). We investigated factors associated with viral rebound with Poisson 
regression. These results were used to calculate the rate of viral rebound according to several key factors, including 
age, calendar year at start of ART, and time since baseline.
Findings Of the 16 101 people included, 4519 had a first viral rebound over 58 038 person-years (7·8 per 100 person-years, 
95% CI 7·6–8·0). Of the 4519 viral rebounds, 3105 (69%) were defined by measurement of a single viral load of more 
than 200 copies per mL, and 1414 (31%) by a documented treatment interruption. The rate of first viral rebound 
declined substantially over time until 7 years from baseline. The other factors associated with viral rebound were 
current age at follow-up and calendar year at ART initiation (p<0·0001) and HIV risk group (p<0·0001); higher pre-
ART CD4 count (p=0·0008) and pre-ART viral load (p=0·0003) were associated with viral rebound in the multivariate 
analysis only. For 1322 (29%) of the 3105 people with observed viral rebound, the next viral load value after rebound 
was 50 copies per mL or less with no regimen change. For HIV-positive men who have sex with men, our estimates 
suggest that the probability of first viral rebound reaches a plateau of 1·4% per year after 45 years of age, and 1·0% 
when accounting for the fact that 29% of viral rebounds are temporary elevations.
Interpretation A substantial proportion of people on ART will not have viral rebound over their lifetime, which has 
implications for people with HIV and the planning of future drug development.
Funding UK Medical Research Council.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. 
Introduction
The goal of antiretroviral therapy (ART) for people 
infected with HIV is to achieve and maintain continuous 
maximal virological suppression to allow immune recon­
stitution, minimise the risk of resistance emergence,1–4 
prevent HIV­related morbidity and mortality, and to 
prevent transmission.1–9 Most people starting treatment 
now achieve virological suppression within around 
3–6 months.10–12 Rates of viral rebound have decreased 
over the years and the risk of rebound decreases with 
increasing duration of viral suppression.13–17 However, 
although current regimens seem to be durably effective, 
the extent to which people living with HIV will be able to 
sustain sufficient adherence to maintain viral suppression 
on ART in the long term is unknown. Few studies have 
estimated the long­term rate of viral rebound in people 
who initially achieved viral suppression. No study that we 
could identify has investigated the factors associated with 
the rate of viral rebound and used such findings to project 
rates of viral rebound over a lifetime or calculated the 
implied probability of requiring only one ART regimen in 
a lifetime. With the number of people on ART world wide 
approaching 20 million, this information is of public 
health significance worldwide.
The UK Collaborative HIV Cohort (UK CHIC) Study 
includes data from long­term follow­up of a large and 
diverse cohort of people living with HIV. In the analysis 
reported here, we aimed to estimate the long­term rate of 
first viral rebound and to identify associated factors in 
people who achieve viral suppression after ART initiation. 
We then used these rate estimates to predict long­term 
durability of viral suppression.
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Methods
Study design and participants
UK CHIC is an ongoing multicentre cohort study that 
collates routinely collected data from HIV­positive 
individuals aged 16 years and older who have been 
seen for care at at least one of 21 clinical centres in the 
UK. The study details are described elsewhere.18 In 
brief, centres collect data on demographic information, 
ART treatment history, laboratory results, and AIDS 
diagnoses. Start and stop dates for ART drugs are 
obtained from a review of clinical notes in some clinics 
and from pharmacy records in others.
These analyses are based on the 2014 update of the UK 
CHIC Study. An individual was eligible for inclusion 
if they met the following criteria: started ART for the 
first time (with a regimen containing three or more 
antiretroviral drugs) between Jan 1, 1998, and May 31, 2013; 
had at least 9 months of follow­up since the start of ART; 
and was on ART 9 months after ART initiation with a 
most recent viral load (measured 3–9 months after 
starting ART) of 50 copies per mL or less. We excluded 
anyone with pre­ART viral loads (most recently measured 
viral load at ART initiation) of 50 copies per mL or less (or 
if undetectable when the lower limit of detection was 
>50 copies per mL) because we suspected unrecorded 
previous ART use. The baseline for these analyses was 
defined as 9 months after ART initiation.
The UK CHIC Study received approval by the 
West Midlands multicentre research ethics committee 
(MREC/00/7/47) and by local ethics committees and, 
following UK regulations, does not require individual 
informed consent.
Procedures
Viral rebound was defined as either a single viral load of 
more than 200 copies per mL or a documented treatment 
interruption (a record of no ART use for ≥1 month). We 
used a single viral load to define viral rebound because 
practical data limitations can mean that a confirmatory 
viral load is not available within a suitable timeframe and 
because physician intervention might occur after the first 
viral load of more than 200 copies per mL. However, a 
single viral load value of more than 200 copies per mL 
can often be followed by a value of 50 copies per mL or 
less without any change in regimen, so we also calculated 
the proportion of people who had viral rebound who 
went on to achieve resuppression without a change in 
ART regimen.
Individuals were followed up from baseline until 
whichever of the following events occurred first: viral 
rebound; start of a gap in viral load measures of at 
least 12 months; last follow­up (date of last viral load 
measurement or last update on treatment information); 
or 15 years from baseline.
Statistical analysis
We calculated the incidence of first viral rebound 
(number of first viral rebounds per person­year of follow­
up) stratified by time since study baseline.
We did several sensitivity analyses in which we 
considered alternative definitions of first viral rebound 
with the following modifications: not counting treatment 
interruption as a rebound; censoring follow­up at the date 
of treatment interruption instead of defining it as viral 
rebound; including loss to follow­up as a component 
of the viral rebound endpoint (ie, a gap in viral load 
measurements of ≥12 months or follow­up no longer 
occurring at a UK CHIC site, which cover approximately 
40% of people diagnosed with HIV after Jan 1, 2013, in the 
UK); defining viral rebound as the first of two consecutive 
viral load measurements of more than 200 copies per mL, 
including treatment interruption; and without censoring 
follow­up when a gap in viral load measurements of more 
than 12 months occurred.
Poisson regression (PROC GENMOD in SAS 
version 9.4) was used to identify factors potentially 
associated with viral rebound. Follow­up was divided into 
1 month periods for this analysis. Factors considered 
Research in context
Evidence before this study 
Many studies have looked at viral load outcomes in people on 
antiretroviral therapy (ART) and they have generally described 
high viral load suppression with modern regimens. We searched 
Web of Knowledge using the following search terms: “hiv*” 
AND “vir*” AND (“rebound” OR “failure”) AND “rate” AND 
“antiretroviral”, restricting to English language with no 
publication date restrictions, on Sept 28, 2016. Very few studies 
have estimated the long-term incidence of viral rebound in 
people who have initially achieved viral suppression. No studies 
that we could identify have assessed the factors associated with 
viral rebound and used such findings to project incidence of 
viral rebound over a lifetime or calculated the implied 
probability of requiring only one ART regimen in a lifetime. 
Added value of this study 
We show that in individuals who start ART and achieve viral 
load suppression on a first-line regimen, incidence of first viral 
rebound is low and declines over at least 7 years before 
stabilising at a low level—as low as 1% per year in some 
demographic groups.
Implications of all the available evidence 
A substantial proportion of people on ART will not have viral 
rebound on their first-line regimen over their lifetime. Sufficient 
adherence to achieve lIfetime suppression of HIV viral 
replication is achievable with modern antiretroviral regimens, 
further supporting the strategy of maximising diagnosis of HIV 
and ART initiation, for personal and public health benefit.
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were age at a given month of follow­up (which we termed 
current age), HIV­acquisition risk group, time from 
baseline to a given month of follow­up, calendar year at 
ART initiation, and pre­ART viral load and CD4 count. 
We categorised the length of time from baseline to a 
given month of follow­up into groups (<1 year, 1–2 years, 
2–3 years, 3–4 years, 4–5 years, 5–6 years, 6–7 years, and 
>7 years). Times from baseline to follow­up longer than 
7 years were combined into a single category, because our 
analyses revealed no statistically significant trend over 
follow­up times after 7 years. We recognise that the 
absence of statistically significant evidence for a decline 
in viral rebound rate after 7 years does not exclude the 
possibility that there was some decline in rate that was 
not detected because of low statistical power. However, 
for our projections we adopted the conservative 
assumption of no further decline. We used a similar 
approach to defining an upper cutoff for both calendar 
year at start of ART (2008) and current age at follow­up 
(45 years). Calendar year at start of ART was categorised 
into Jan 1, 1998, to Dec 31, 1999; 2000–01; 2002–03; 
2004–05; 2006–07; and Jan 1, 2008 onwards. Current age 
was categorised into younger than 20 years; 20–25 years; 
25–30 years; 30–35 years; 35–40 years; 40–45 years; and 
45 years and older. For both calendar year and age, lower 
rates of viral rebound were associated with later calendar 
year and older age, respectively, and so again our 
approach was conservative in assuming a constant rate 
above the highest cutoff. In the first multivariable model 
we included the starting regimen and the pre­ART viral 
load and CD4 count. In the second multivariable model 
we excluded these factors to give a simpler model with 
no missing data, to be used for projecting future 
viral rebound rates for individuals with different 
characteristics. Projections for these individuals were 
generated by use of model parameter estimates to obtain 
an estimated incidence of first viral rebound for each 
year of a person’s life, taking account of their age at 
assessment and the calendar year at start of ART, and the 
time since baseline. These estimates were then used to 
determine the cumulative probability of not having viral 
rebound, which enabled calculation of estimates of 
cumulative survival without viral rebound and the 
inverse, cumulative risk of having viral rebound, by a 
given age. These estimates are conditional on the person 
living to that age. We calculated the risk of viral rebound 
and rebound­free survival rather than estimating 
the probability of having survived to and avoided viral 
rebound by a particular age because the latter is dependent 
on the mortality rate. Estimates of the probability of 
having survived to and avoided viral rebound by a specific 
age can be derived by readers from our estimated rates of 
viral rebound for any given set of age­specific mortality 
rates.
All analyses were done with SAS software (version 9.4; 
SAS Institute, Cary, NC, USA). All tests of significance 
were two­sided.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
We identified 27 734 people who started ART with three 
or more drugs on or after Jan 1, 1998. Of these, 19 094 had 
at least one viral load measurement between 3 months 
after the start of ART and baseline (9 months after start 
of ART), and at least 1 day of follow­up after baseline; of 
Participants 
(n=16 101)
Age at start of ART (years) 37 (32–44)
Female sex 4050 (25%)
HIV risk-group, ethnicity, sex 
Black African heterosexual men 1529 (9%)
Black African heterosexual women 2687 (17%)
Men who have sex with men 8642 (54%)
Non-black heterosexual men and women 2144 (13%)
Injectable drug users (past and present) 284 (2%)
Unknown 815 (5%)
Women pregnant at start of ART 372 (2%)
Starting regimen type
Non-nucleoside reverse transcriptase inhibitor 
based
11 599 (72%)
Ritonavir-boosted protease inhibitor based 3333 (21%)
Unboosted protease inhibitor 654 (4%)
Nucleoside or nucleotide-only 515 (3%)
Calendar year of start of ART
1998–99 1058 (7%)
2000–01 1358 (8%)
2002–03 1816 (11%)
2004–05 2183 (14%)
2006–07 2439 (15%)
2008–09 3111 (19%)
2010–11 2866 (18%)
2012–13 1270 (8%)
Pre-ART viral load (copies per mL)*
51–500 464 (3%)
501–5000 1069 (7%)
5001–20 000 2063 (14%)
20 001–100 000 4852 (33%)
100 001–500 000 4864 (34%)
>500 000 1174 (8%)
Pre-ART HIV viral load (log10 copies per mL)* 4·9 (4·3–5·3)
Pre-ART CD4 count (cells per µL)† 217 (120–310)
Time from baseline‡ to end of follow-up (years) 2·6 (1·1–5·2)
Data are median (IQR) or n (%). ART=antiretroviral therapy. *Available for 
14 486 individuals. †Available for 14 519 individuals. ‡Baseline is defined as 
9 months after ART inititiation. 
Table 1: Characteristics of people included in the analyses
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these 19 094 individuals, 16 101 (84%) also had a viral load 
of 50 copies per mL or less at baseline, and were included 
in the analysis (table 1). The earliest baseline date was 
Oct 1, 1998, and the latest was Feb 21, 2014. The latest end 
of follow­up date was Nov 22, 2014. The median number 
of viral load measurements per person was seven 
(IQR 3–17), and the median number of years of follow­up 
was 2·6 (1·1–5·2), with 13 463 person­years after year 5 
and 1847 person­years after year 10. Viral load monitoring 
occurred at a median frequency of every 4·4 months 
(IQR 3·2–5·0). The 16 101 people included in the 
analysis differed from the 11 633 excluded people in the 
proportion of women (4050 [25%] in the participants vs 
3813 [33%] in the excluded individuals) and the proportion 
of men who have sex with men (MSM; 8642 [54%] vs 5107 
[44%]); the two groups did, however, have a similar 
median age (37 years [IQR 32–44] vs 35 years [30–42]).
4519 first viral rebounds were observed over 58 038 person­
years, giving an overall rate of first viral rebound of 
7·8 (95% CI 7·6–8·0) per 100 person­years. Of the 
4519 participants with a first viral rebound, 3105 (69%) 
had a single viral load of more than 200 copies per mL 
and 1414 (31%) had a documented treatment interruption. 
Of the 3105 people who had a viral load of more than 
200 copies per mL, 2999 (97%) had a subsequent viral 
load value available. 1377 (46%) of the 2999 people 
achieved virological resuppression, and 1322 (44% of the 
2999 with a subsequent viral load; 29% of all 3105 with 
viral rebound) achieved virological resuppression without 
a change in ART regimen. Of the 1622 people who did 
not have virological resuppression at the subsequent 
viral load measure, the median value of the subsequent 
viral load was 906 copies per mL (IQR 209–13 461); 
792 individuals (49%) had more than 1000 copies per mL, 
436 (27%) had more than 10 000 copies per mL, and 
157 (10%) had more than 100 000 copies per mL.
Incidence of viral rebound clearly decreased over 
time since baseline (figure). The rate was 12·6 per 
100 person­years in year 1 and declined to 2·5 per 
100 person­years in years 10–15 combined. To identify the 
timepoint at which the decline in viral rebound rate was 
no longer statistically significant, we first fitted a 
univariable Poisson regression model of the association 
between time from baseline and the rate of viral rebound. 
Overall, considering all follow­up time from baseline to 
15 years after, a highly statistically significant declining 
trend in rate was seen (16% per year; p<0·0001). 
When we restricted inclusion of follow­up to person­
years after year 1 from baseline, the declining trend 
remained (13% per year; p<0·0001). When we restricted 
inclusion to follow­up after 2 years (11%; p<0·0001), 
3 years (11%; p<0·0001), 4 years (11%; p<0·0001), 5 years 
(11%; p<0·0001), or 6 years (9%; p=0·003) from baseline, 
the statistically significant decline persisted. However, 
when we restricted inclusion to follow­up after 7 years 
(5% decline; p=0·27) or 8 years (3% decline; p=0·68), the 
trend was no longer statistically significant. By restricting 
inclusion to follow­up before year 7, the average decline 
in rate of rebound between year 1 and year 7 was 18% per 
year (unadjusted rate ratio 0·82 per year, 95% CI 
0·80–0·84; p<0·0001). The strong effect of time 
from baseline persisted, and even strengthened, after 
adjustment for other covariates (table 2).
In addition to time from baseline, older age and more 
recent calendar year at start of ART were both associated 
with reduced rates of viral rebound (table 2). Black 
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Figure: Incidence of first viral rebound by time since study baseline (9 months after start of ART)
Error bars show 95% CI.
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African men and black African women had significantly 
higher rates of viral rebound than men who have sex 
with men. Higher pre­ART viral load and higher pre­
ART CD4 count were associated with higher rates of 
viral rebound in the multivariable model but not the 
univariable model.
We considered whether predictors of viral rebound 
were similar for the first 5 years of follow­up and the 
subsequent follow­up period (data not shown). We found 
only one significant interaction: being on a regimen 
other than a non­nucleoside reverse transcriptase 
inhibitor­based regimen or a ritonavir­boosted protease 
inhibitor­based regimen at baseline was associated with a 
reduced risk of viral rebound after 5 years.
When assessing alternative definitions of viral rebound, 
we observed a decrease over time from baseline in the 
rate of first viral rebound in all sensitivity analyses 
(table 3).
We used the estimates derived from the simplified 
multivariable Poisson regression model (multivariable 
model 2; table 2) to project the cumulative risk of viral 
rebound by particular ages, conditional on survival to 
that age. For an MSM who started ART after 2008 and 
achieved initial viral load suppression by 9 months from 
the start of ART at age 35 years, the probability of first 
viral rebound is 24% (18% if accounting for the fact that 
29% of viral rebounds are temporary elevations in viral 
load) by age 40 years, 48% (38%) by 65 years, and 60% 
(49%) by 85 years (table 4). For comparison, the 
probability of viral rebound by age 85 years for people in 
various example situations are as follows: MSM aged 
18 years at the start of ART, 72% (64% if accounting for 
temporary elevations); black African heterosexual man 
aged 35 years at the start of ART, 80% (68%); MSM aged 
45 years who has been on ART for 8 years without having 
had first­line viral rebound, 43% (33%). Our estimates 
suggest that the rate of rebound reaches a plateau of 
1·4% per year in MSM older than 45 years, and 1·0% 
when accounting for the fact that 29% of viral rebounds 
are temporary elevations.
Discussion
In people starting ART who have achieved viral load 
suppression on a first­line regimen started after 2008, rates 
of viral rebound are low and decline over 7 years to a low 
plateau. In MSM older than 45 years, the estimated plateau 
rate is 1·4% per year. When considering that 29% of viral 
rebounds consisted of a single measurement of more than 
200 copies per mL followed by a subsequent measurement 
of 50 copies per mL or less, the rate is around 1% per year. 
These results suggest that many people on ART will not 
have viral rebound over their lifetime.
We have previously reported (based on data from a 
shorter follow­up) the decreasing rate of viral rebound 
with increasing time of viral suppression in people 
visiting UK clinics.14,16 In this Article, we extend that 
observation with up to 15 years of follow­up and 
substantially greater numbers of participants. One 
explanation for the decrease in rate of first viral rebound 
is that individuals each have their own tendency to 
adhere to treatment, which is constant over time, so 
as viral rebounds occur, the remaining population 
becomes one containing the most adherent individuals. 
Another is that people’s behaviour changes over time 
and they become accustomed to taking antiretroviral 
drugs once the drugs are integrated into their everyday 
lifestyles. A third potential contributing factor is that 
viral suppression can be maintained with decreasing 
adherence over time.19
Univariable Multivariable 1 Multivariable 2*
Time from baseline (years)
<1 1 1 1
1–2 0·73 (0·67–0·79) 0·72 (0·66–0·79) 0·72 (0·67–0·78)
2–3 0·58 (0·53–0·64) 0·58 (0·53–0·64) 0·57 (0·52–0·63)
3–4 0·46 (0·41–0·52) 0·43 (0·38–0·49) 0·44 (0·39–0·50)
4–5 0·43 (0·38–0·49) 0·41 (0·36–0·47) 0·40 (0·35–0·45)
5–6 0·38 (0·32–0·44) 0·34 (0·29–0·40) 0·34 (0·29–0·39)
6–7 0·35 (0·30–0·42) 0·28 (0·23–0·35) 0·30 (0·25–0·36)
≥7 0·24 (0·21–0·28) 0·18 (0·15–0·21) 0·19 (0·16–0·22)
p value p<0·0001 p<0·0001 p<0·0001
Current age (years)
<20 1 1 1
20–25 0·53 (0·37–0·76) 0·47 (0·31–0·70) 0·57 (0·39–0·81)
25–30 0·45 (0·32–0·63) 0·41 (0·28–0·61) 0·50 (0·36–0·70)
30–35 0·44 (0·32–0·61) 0·41 (0·28–0·59) 0·50 (0·36–0·70)
35–40 0·39 (0·28–0·54) 0·39 (0·27–0·57) 0·45 (0·32–0·63)
40–45 0·39 (0·28–0·54) 0·37 (0·25–0·54) 0·45 (0·32–0·63)
≥45 0·34 (0·25–0·48) 0·34 (0·23–0·49) 0·41 (0·29–0·57)
p value p<0·0001 p<0·0001 p<0·0001
HIV risk group
Men who have sex with men 1 1 1
Black African men 1·88 (1·70–2·05) 1·88 (1·70–2·09) 1·79 (1·63–1·95)
Black African women 1·60 (1·48–1·72) 1·65 (1·51–1·79) 1·51 (1·39–1·63)
Other 1·36 (1·25–1·48) 1·36 (1·25–1·49) 1·32 (1·22–1·42)
p value p<0·0001 p<0·0001 p<0·0001
Calendar year of ART initiation
1998–99 1·32 (1·20–1·46) 2·20 (1·95–2·46) 2·16 (1·95–2·37)
2000–01 1·06 (0·88–1·16) 1·63 (1·46–1·82) 1·65 (1·49–1·82)
2002–03 0·97 (0·88–1·06) 1·38 (1·25–1·54) 1·39 (1·27–1·54)
2004–05 0·94 (0·86–1·03) 1·20 (1·09–1·34) 1·23 (1·12–1·35)
2006–07 1·00 (0·90–1·09) 1·22 (1·10–1·34) 1·20 (1·09–1·32)
2008 onwards 1 1 1
p value p<0·0001 p<0·0001 p<0·0001
Pre-ART CD4 count (per 100 cells 
per μL increase)
1·01 (0·99–1·03); 
p=0·51
1·04 (1·02–1·06); 
p=0·0008
Not included in model
Pre-ART viral load (per log10 increase) 1·00 (0·97–1·04); 
p=0·86
1·08 (1·04–1·12); 
p=0·0003
Not included in model
Values are rate ratio (95% CI). p value for categorical variables is global p value (likelihood ratio test). Results from 
univariable and multivariable Poisson regression models. ART=antiretroviral therapy. *Model intercept=–1·72. 
Table 2: Factors associated with first viral rebound
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In agreement with other studies, we found that older 
age15,16 and later calendar year13,20 at start of ART were 
associated with a reduced risk of viral rebound. Older 
age is associated with better adherence,21,22 which could 
explain the reduced rate of rebound in older people in 
our study. Older people might face problems with taking 
ART because of polypharmacy and incidence of 
comorbidities, but we found evidence of a lower risk of 
rebound at older ages, even though there was no trend 
after age 45 years. The effect of calendar year is likely to 
be explained by the use of less toxic, more effective 
drugs in more recent years, which are easier for people 
to tolerate, but could also be because of improvements 
in the management of toxic effects and of general health 
over time. Additionally, we found that being of black 
African origin is associated with a moderately increased 
risk of viral rebound, as was found in a protease 
inhibitor monotherapy trial in the UK.23 The reasons for 
this increased risk are uncertain, although they might 
relate to socioeconomic conditions or inconsistent 
prioritisation of ART adherence over other challenges of 
daily life. We are uncertain about extrapolation of our 
findings to Africans living in sub­Saharan Africa, 
because the lower socioeconomic conditions and greater 
hardships resulting from taking time from work and 
getting to a clinic in these settings might mean that 
rebound rates would be higher than in our study.24–26 
However, the proportion of people reported to be on 
ART and to have viral loads of less than 1000 copies per mL 
from studies and routine data from sub­Saharan 
Africa,12 most recently from the population­based HIV 
impact assessments surveys in Malawi (91%), Zimbabwe 
(87%), and Zambia (89%), suggest that durability of 
virological suppression could be at least as great in 
Africa as in the UK.27
The possible cause of viral rebound after many years of 
virological suppression is unknown, and we found no 
evidence for a limit of durability of ART efficacy. Occasional 
life events could result in suboptimal adherence that leads 
to viral rebound. We found that being on regimens other 
than a non­nucleoside reverse transcriptase inhibitor­
based regimen or a ritonavir­boosted protease inhibitor­
based regimen at baseline was associated with a reduced 
risk of viral rebound after 5 years, but we cannot rule out 
the possibility that this finding might be a type I error.
As in other studies,28 we found that a higher viral load 
at the start of ART was associated with an increased risk 
of viral rebound in our first multivariable model 
(although not in our univariate model). After adjustment 
for viral load at ART initiation in the first multivariable 
model, we found that a higher CD4 count at the start of 
ART was also associated with a higher rate of viral 
rebound; however, we are unsure of the reason for this 
result. This association is not accounted for by temporary 
use of ART in pregnant women, for example, because 
the effect was stronger in men (data not shown).
1 year 2 years 3 years 4 years 5 years 6 years 7 years 8 years 9 years 10 years 11 years 31 years 51 years
Age (years) 35 36 37 38 39 40 41 42 43 44 45 65 85
Primary viral rebound endpoint
Rate of viral rebound (per 100 person-years) 8·1  5·8 4·6 3·6 3·2 2·8 2·5 1·5 1·5 1·5 1·5 1·4 1·4
Cumulative probability of first-line viral 
rebound 
8% 13% 17% 20% 22% 24% 26% 27% 29% 30% 31% 48% 60%
Primary viral rebound endpoint not including temporary elevations* 
Rate of viral rebound (per 100 person-years) 5·8 4·1 3·3 2·6 2·3 2·0 1·8 1·1 1·1 1·1 1·0 1·0 1·0
Cumulative probability of first-line viral 
rebound
6% 9% 12% 15% 17% 18% 20% 21% 21% 22% 23% 38% 49%
Example of an MSM aged 35 years at 9 months after the start of ART, who has achieved viral suppression of less than 50 copies per mL. Rate is calculated on the basis of parameter estimates from the 
multivariable model 2 in table 2, including the intercept estimate of –1·72. For example, the viral rebound rate within 1 year from baseline is: exp(–1·72) × 1·00 (rate ratio for <1 year since ART initiation) × 0·45 
(rate ratio for age category) × 1·00 (rate ratio for MSM) × 1·00 (rate ratio for ART started in 2008 onwards)=8·1 per 100 person-years. The viral rebound rate at 1–2 years from baseline is: exp(–1·72) × 0·72 (rate  
for years 1–2) × 0·45 × 1·00 × 1·00=5·8 per 100 person-years. So the probability of not having had viral rebound by 1 year from baseline is exp(–viral rebound rate in year 1)=0·922, and the probability of having had 
viral rebound is 0·078 (rounded to 8%). The probability of not having had viral rebound by 2 years from baseline is: –exp(–viral rebound rate in year 2) × 0·922=0·870, and the probability of having had viral 
rebound=0·130 (13%). ART=antiretroviral therapy. exp=exponential. MSM=man who has sex with men. *Viral rebound after which the next viral load was <50 copies per mL without any change in ART regimen.
Table 4: Example projections of durability of first-line regimen without viral rebound (assuming ART is started after 2008) in an MSM aged 35 years at different times after ART initiation
Overall From year 7 
onwards
Primary viral rebound endpoint* 7·8 (7·6–8·0) 3·0 (2·6–3·5)
Not including treatment interruption 6·0 (5·8–6·2) 2·3 (1·9–2·7)
Not including treatment interruption 
but censoring follow-up at the date of 
treatment interruption
5·3 (5·2–5·5) 2·1 (1·8–2·4)
Including loss to follow-up† 13·7 (13·4–14·0) 8·3 (7·6–9·0)
Two consecutive viral load measures 
of >200 copies per mL, including 
treatment interruption
4·9 (4·7–5·1) 2·0 (1·7–2·3)
Not censoring follow-up when a gap 
in viral load measurement of 
>12 months occurred
7·8 (7·6–8·0) 3·4 (3·0–3·8)
Data are incidence of viral rebound per 100 person-years (95% CI). *A single viral 
load of >200 copies per mL or treatment interruption (for ≥1 month). †Defined as 
no viral load measure for ≥12 months or no follow-up after Jan 1, 2013.
Table 3: Effect of alternative definitions of viral rebound on the rate of 
viral rebound 
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To our knowledge, this is the largest study to provide 
long­term estimates of rates of first viral rebound for up 
to 15 years after ART initiation. Our estimates provide 
guidance to ART clinics on the expected rates of first 
viral rebound in people on first­line ART. The results 
also have implications for the risk associated with 
condomless sex because of unidentified viral rebound 
having occurred since the last measure.
The findings presented in this Article should be 
interpreted in the context of several limitations. Our 
results are based on people who have not had previous 
viral rebound and should not be extrapolated to people 
who do not manage to achieve a good initial virological 
response to ART in a suitable timeframe or who are 
receiving second or subsequent lines of ART. Further, 
we did not collect data on several factors that are likely 
to be important determinants of adherence, including 
socioeconomic status, housing stability, drug and 
alcohol use, mental health diagnoses, and incarceration. 
We did not collect data on reasons for treatment 
interruption, and data on interruptions might be 
incomplete. We cannot rule out that some people who 
were no longer being followed up in the UK CHIC 
Study did have viral rebound after they left their 
participating clinic. Our sensitivity analysis in which 
people who were no longer being followed up in the UK 
CHIC Study were defined as having had viral rebound 
resulted in a 76% higher rate of viral rebound compared 
with our primary definition. However, many of the 
participants who fulfilled our definition of having viral 
rebound did not have true first­line treatment failure (ie, 
as a result of drug resistance), and could have continued 
with a first­line regimen even after fulfilling our 
definition. Another caveat is that we censored follow­up 
in people who were lost to follow­up or died. Such 
censoring could have led to bias in our rebound rates 
because the subsequent rate of viral rebound could be 
different in those whose follow­up was censored because 
of loss to follow­up, than in those in whom it was not. 
We did not consider the assay used to measure viral 
load, but previous studies have found that the rate of 
rebound depends on the assay used.23
In summary, rates of viral rebound in people with long­
term viral suppression on first­line regimens have 
become extremely low, which suggests that many people 
on ART will not have viral rebound over their lifetime.
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